Cited by 83HIV Research and TreatmentHIV/AIDS drug development and treatmentVirus-based gene therapy research

A Strongly Transdominant Mutation in the Human Immunodeficiency Virus Type 1 gag Gene Defines an Achilles Heel in the Virus Life Cycle

Open access
Lee, Sook-Kyung, Harris, Janera, Swanstrom, Ronald·2009·Journal of Virology

Abstract

The human immunodeficiency virus type 1 (HIV-1) protease (PR) makes five obligatory cleavages in the viral Gag polyprotein precursor. The cleavage events release the virion structural proteins from the precursor and allow the virion to undergo maturation to become infectious. The protease cleavage between the matrix protein (MA) domain and the adjacent capsid protein (CA) domain releases CA from the membrane-anchored MA and allows the N terminus of CA to refold into a structure that facilitates the formation of hexamer arrays that represent the structural unit of the capsid shell. In this study, we analyzed the extent to which each of the HIV-1 Gag processing sites must be cleaved by substituting the P1-position amino acid at each processing site with Ile. A mutation that blocks cleavage at the MA/CA processing site (Y132I) displayed a strong transdominant effect when tested in a phenotypic mixing strategy, inhibiting virion infectivity with a 50% inhibitory concentration of only 4% of the mutant relative to the wild type. This mutation is 10- to 20-fold more potent in phenotypic mixing than an inactivating mutation in the viral protease, the target of many successful inhibitors, and more potent than an inactivating mutation at any of the other Gag cleavage sites. The transdominant effect is manifested as the assembly of an aberrant virion core. Virus containing 20% of the Y132I mutant and 80% of the wild type (to assess the transdominant effect on infectivity) was blocked either before reverse transcription (RT) or at an early RT step. The ability of a small amount of the MA/CA fusion protein to poison the oligomeric assembly of infectious virus identifies an essential step in the complex process of virion formation and maturation. The effect of a small-molecule inhibitor that is able to block MA/CA cleavage even partially would be amplified by this transdominant negative effect on the highly orchestrated process of virion assembly.

Integrity signals

Registry

Crossref · 10.1128/jvi.00317-09

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Abolishing or altering the rates of cleavage at individual sites leads to maturation and core morphology defects and loss of infectivity.

    “Abolishing or altering the rates of cleavage at individual sites leads to maturation and core morphology defects [64][65][66][67] and loss of infectivity”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lee, S.-K., Harris, J., & Swanstrom, R.
Affiliations
University of North Carolina at Chapel Hill (US)
Corresponding author
Swanstrom, Ronald
Venue
Journal of Virology
Published
2009-09
Volume
83
Issue
17
Pages
8536-8543
ISSN
  • 0022-538X (ISSN-L)
  • 1098-5514
OpenAlex
W2142892346
Cited by
83
References
4
Citations by year
2025: 3 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 5 · 2015: 10 · 2014: 5 · 2013: 8 · 2012: 3
FWCI
2.03
Type
journal article
Language
en
Open access
Locations
  • Journal of Virology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • National Institutes of Health (AI50410, CA-16086, GM066524)
  • Center for AIDS Research, University of Washington (P30 AI-50410, AI50410)
  • National Cancer Institute (P30CA 16086, P30CA016086)
  • National Institute of General Medical Sciences (P30-GM066524, P01GM066524)
  • National Institute of Allergy and Infectious Diseases (P30 AI50410, P30AI050410)
  • Center for AIDS Research, University of North Carolina at Chapel Hill (P30 AI‐50410)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
HIV-1, Gag protein, proteolytic cleavage sites, capsid protein, viral assembly, virion maturation, infectivity, phenotypic mixing, protease inhibitors, reverse transcription
MeSH terms
Animals, Humans, Protein Processing, Post-Translational, Virus Replication, HIV Antigens, HIV-1, Mutagenesis, Site-Directed, HIV Protease, HIV Core Protein p24, Virus Assembly, Amino Acid Substitution, Mutation, Missense, gag Gene Products, Human Immunodeficiency Virus, Protein Multimerization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review